Optimizing local treatments for ALK-positive lung cancer on brigatinib
Part of Cancer, Lungs & breathing clinical trials.
This trial is for people with advanced ALK-positive lung cancer who are already taking the targeted therapy brigatinib and have a few remaining spots of cancer. It tests whether adding local treatments (like surgery, focused radiation, or ablation) to the remaining spots can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with stage 3 or 4 non-small cell lung cancer that has an ALK gene change.
- You cannot have had any previous targeted therapy (TKI) for ALK.
- You must have been on brigatinib for at least 3 to 9 months and your cancer is either stable or has shrunk, but not completely gone.
- You should have 5 or fewer cancer spots (metastases) in your body, and no more than 2 in one organ.
- You must be healthy enough to have local treatments like surgery, focused radiation, or heat/cold ablation for those spots.
- Your liver, kidney, and blood counts need to be within certain ranges, and you must be willing to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This trial compares two treatment plans for stage III lung cancer that can't be removed by surgery. It tests whether starting with a combination of immunotherapy, targeted therapy, and chemotherapy before usual chemoradiation works better than the usual approach, and whether continuing immunotherapy after treatment helps people live longer.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.